Using synthetic PreImplantation Factor and cooling to treat brain injury in newborns
Synthetic PreImplantation Factor (sPIF) plus hypothermia to treat neonatal brain injury
This study is looking at a new treatment for newborns with brain injuries from a lack of oxygen, combining a special substance called synthetic PreImplantation Factor with cooling therapy to see if it can help protect their brains and improve their long-term health.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Bioincept, LLC NIH-funded |
| Lab location | 1 site (Mason, UNITED STATES) |
| Project ID | NIH-11078710 on NIH RePORTER |
What this research studies
This research investigates the use of synthetic PreImplantation Factor (sPIF) combined with hypothermia to treat neonatal brain injuries caused by hypoxic-ischemic encephalopathy (HIE). The approach aims to enhance neuroprotection during the critical period following brain injury by administering sPIF alongside hypothermia, which is already used to mitigate damage in affected infants. The study will evaluate the effectiveness of this combination therapy in improving neurological outcomes and reducing long-term disabilities in newborns. By focusing on the acute phase of HIE, the research seeks to provide a new therapeutic option for infants suffering from this serious condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are newborns diagnosed with hypoxic-ischemic encephalopathy who are experiencing acute brain injury.
Not a fit: Patients who do not have hypoxic-ischemic encephalopathy or those who are not newborns may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for newborns with brain injuries, potentially reducing long-term disabilities and enhancing recovery.
How similar studies have performed: While hypothermia has shown some effectiveness in treating HIE, the combination of sPIF with hypothermia is a novel approach that has not been extensively tested in clinical settings.
Where this research is happening
Mason, UNITED STATES
- Bioincept, LLC — Mason, United States (Active)
Researchers
- Principal investigator: Barnea, Eytan R — Bioincept, LLC
- Study coordinator: Barnea, Eytan R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.